Real-world evidence on clearing hrHPV infection
Real-world studies can provide better understanding of how a treatment is used in routine clinical practice. Real-world data enable a greater appreciation of the true efficacy and safety profile of a treatment in the real world, by reflecting the actual diagnosis, treatment process and health status of patients under real conditions. In a recent real-world study of 506 patients at nine hospitals in seven Chinese provinces (Figure S1), 69.57% of hrHPV-positive patients became hrHPV-negative following treatment (Table 2).24 These real-world data are in agreement with the results of our two previous independent parallel clinical studies.13 This real-world study further revealed the diversity among different hrHPV subtypes. The clearance rates of hrHPV subtypes 16, 18, and 52 were 77.78%, 85.37%, and 61.11%, respectively (Table 2). The real-world study also revealed there was no significant side effect during the treatment and all follow-ups, beside mild vaginal itch occasionally observed during treatments24, which is in line with our previous clinical studies13-14. This study further supports the safety and efficacy of REBACIN® as a non-invasive clinical regimen for the clearance of persistent hrHPV infections.24